文献速递类风湿关节炎

利妥昔单抗可能通过降低外泌体微小RNA-155导致类风湿关节炎患者丙型肝炎病毒血症增加

Rituximab May Cause Increased Hepatitis C Virus Viremia in Rheumatoid Arthritis Patients Through Declining Exosomal MicroRNA-155.
PubMed 文献 · Arthritis Rheumatol · 2018-06-27

研究探讨利妥昔单抗增强丙型肝炎病毒(HCV)活性的机制。体外实验显示B细胞来源的miR-155经外泌体传递可抑制肝细胞中HCV复制,利妥昔单抗诱导B细胞耗竭并影响miR-155产生及外泌体传递,从而增强HCV活性(P < 0.005)。RA合并HCV感染者血清外泌体及外泌体miR-155水平高于无HCV感染者(P < 0.01),利妥昔单抗治疗后外泌体miR-155下降(P < 0.01)且HCV载量同时增加(P < 0.05)。

要点

  • B细胞来源miR-155经外泌体传递可抑制肝细胞中HCV复制。
  • 利妥昔单抗可诱导B细胞耗竭并影响miR-155产生及外泌体传递,增强HCV活性(P < 0.005)。
  • RA合并HCV感染者外泌体miR-155升高,利妥昔单抗治疗后下降且HCV载量增加。

核心结论

  • 循环外泌体miR-155水平与HCV载量呈负相关,并与RA患者中利妥昔单抗相关的HCV活性增强相关。
  • 外泌体miR-155可能成为潜在的诊断生物标志物或治疗靶点。

研究设计与样本

  • 采用体外基于细胞的实验检测利妥昔单抗与HCV活性增强的关联。
  • 使用免疫印迹和流式细胞术确认纯化的外泌体,并用酶联免疫吸附试验定量。
  • 采用定量逆转录聚合酶链反应测量外泌体miR-155水平。
  • 比较RA合并HCV感染与无HCV感染患者血清外泌体水平及外泌体miR-155水平。
  • 观察利妥昔单抗治疗前后外泌体miR-155表达变化及HCV载量变化。

主要发现

  • 体外数据显示B细胞来源的miR-155可通过外泌体传递抑制肝细胞中HCV复制。
  • 利妥昔单抗可诱导B细胞耗竭并影响细胞内miR-155产生及外泌体miR-155传递,进而增强肝细胞中HCV活性(P < 0.005)。
  • RA合并HCV感染者血清外泌体水平高于无HCV感染者(P < 0.01)。
  • RA合并HCV感染者外泌体miR-155水平显著高于无感染者(P < 0.01)。
  • 利妥昔单抗治疗后外泌体miR-155表达下降幅度显著大于治疗前(P < 0.01),同时HCV载量增加(P < 0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Several studies have shown that rituximab may enhance hepatitis C virus (HCV) activity. MicroRNAs (miRNAs) have been implicated in modulating the host immune response in HCV infection; miRNAs can be packaged into the exosomes and then shuttled by the exosomes to aid biologic functions. However, the role of exosomal miRNAs (exo-miRNAs) in rituximab-related HCV activity enhancement remains unclear. METHODS: The association between rituximab and increased HCV activity was examined using an in vitro cell-based assay. Purified exosomes were confirmed using immunoblotting and flow cytometry and quantified using enzyme-linked immunosorbent assay. Exosomal miRNA-155 (exo-miR-155) levels were measured using quantitative reverse transcription-polymerase chain reaction. RESULTS: In vitro data showed that B cell-derived miR-155 could inhibit HCV replication in hepatocytes through exosome transmission. Rituximab could both induce B cell depletion and affect intracellular miR-155 production as well as exo-miR-155 transmission and then enhance HCV activity in hepatocytes (P < 0.005). Serum exosome levels were increased in rheumatoid arthritis (RA) patients with HCV infection compared with the levels in RA patients without HCV infection (P < 0.01). The exo-miR-155 levels were significantly increased in RA patients with HCV infection compared with those without infection (P < 0.01). A significantly greater decrement of exo-miR-155 expression was observed after rituximab therapy compared with those observed before therapy (P < 0.01), and hepatitis C viral loads increased simultaneously (P < 0.05). CONCLUSION: Circulating exo-miR-155 levels were negatively correlated with hepatitis C viral loads and subsequently associated with rituximab-related HCV activity enhancement in RA patients. Exo-miR-155 may become a potential diagnostic biomarker or therapeutic target.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Liao TL, Hsieh SL, Chen YM, et al. Rituximab May Cause Increased Hepatitis C Virus Viremia in Rheumatoid Arthritis Patients Through Declining Exosomal MicroRNA-155. Arthritis Rheumatol. 2018. PMID: 29575671. doi:10.1002/art.40495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。